DiaMedica Therapeutics Inc

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DiaMedica Therapeutics addresses FDA concerns amidst financial stability

DiaMedica Therapeutics maintains a strong financial position, but faces challenges with the clinical hold on their pivotal trial, requiring proactive resolution.
Despite increased expenses, the company's commitment to addressing regulatory feedback and ensuring patient safety presents growth opportunities in the long term.
Resolving the clinical hold swiftly and resuming trial enrollment are key priorities for DiaMedica to advance their clinical programs and unlock future potential.

DiaMedica progresses on FDA concerns with stable finances and new leadership

DiaMedica Therapeutics is actively addressing FDA concerns on DM199, supported by a stable financial position and a strengthened management team.
While facing challenges in meeting regulatory requirements and managing increased expenses, DiaMedica sees opportunities in resolving adverse events and advancing DM199.
Overall, DiaMedica's progress, financial stability, and strategic additions position the company well for potential FDA approval and further development of DM199.

DiaMedica Therapeutics reports strong Q2 performance and eyes global expansion

DiaMedica Therapeutics made significant progress in Q2 2023, achieving key milestones, strengthening financial position, and advancing product development.
While facing challenges in patient enrollment and legal matters, the company is well-positioned to capitalize on opportunities for global expansion and market growth.
Overall, DiaMedica's focus on efficient treatment delivery and commitment to innovation position them for future success in the biopharmaceutical industry.

DiaMedica reports solid Q3 results amidst strategic protocol enhancements

DiaMedica Therapeutics showcased robust financials in Q3 2023, driven by successful private placements and strategic cost management.
The appointment of Dr. Ambar Shah and protocol enhancements for ReMEDy2 reflect a commitment to innovation and clinical advancement.
However, challenges persist with patient enrollment, protocol adjustments, and legal proceedings, necessitating focused efforts to mitigate risks and drive progress.

DiaMedica Therapeutics reports robust 2023 performance and advances stroke treatment

DiaMedica Therapeutics' strong financial performance and progress in the ReMEDy2 trial highlight the company's growth potential.
Appointment of a new Chief Medical Officer and protocol revisions demonstrate a commitment to advancing clinical development efforts.
While facing challenges in site commitments and trial complexities, the company has opportunities for global expansion and market penetration.

DiaMedica reports robust Q1 earnings, eyes trial expansion opportunities

DiaMedica Therapeutics showcased strong financial performance and positive trial progress in Q1 2024.
While facing challenges such as increased operating expenses and a legal appeal, the company remains well-positioned for growth.
Opportunities lie in expanding trials, leveraging the success in China, and building a robust foundation for future drug development.

DiaMedica Therapeutics progresses on key programs amidst financial stability

DiaMedica Therapeutics is on track for a transformative 2025 with progress on key programs and enrollment enhancements.
Strategic protocol updates and financial stability bolster the company's position for future growth and clinical success.
Challenges around protocol changes and enrollment optimization require careful navigation for sustained progress.
Opportunities lie in protocol enhancements, regulatory milestones, and financial strength to drive innovation and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call.

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2024 financial results. Updates to ReMEDy2 Acute Isc.

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica's investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is.

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day. Investors and attendees that would like to schedule a meeting with DiaM.

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: T.

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Hive Blockchain Technologies Ltd

IAMGOLD

IAG, DMAC and HIVE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 14, 2024.

Best Momentum Stocks to Buy for October 14th

Clipper Realty

HireQuest Inc

HQI, CLPR, HIVE, DMAC and IAG have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2024.

New Strong Buy Stocks for October 14th

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 s.

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment Conference, September 9-11, New York – Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and p.

DiaMedica Therapeutics Upcoming Conference Participation

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, August 8, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2024 financial results. ReMEDy2 Phase 2/3 AIS Clinical Deve.

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2024 financial results will be released after the markets close on Wednesday, August 7th. DiaMedica will host a live conference call on Thursday, August 8th at 7:00 AM Central Time to provide a business update and discuss financial results.

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025.

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutic.

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximately 4.7 million common shares at a purchase price of $2.50 per share, a premium of approximately 10% above the Company's per share closing price on Tuesday June 25, 2024. Aft.

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement. Pursuant to the terms of t.

DiaMedica Therapeutics Announces $11.8 Million Private Placement

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia. Preeclampsia is a life-threatening pregnancy-associated vascular disorder characterized by new onset hypertension with proteinuria, and/or end org.

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - CFO & Company Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Thomas Flaten - Lake Street François Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024. Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial results. ReMEDy2 Phase 2/.

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.   Confe.

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with its contract research organization (CRO), on re-engaging with study sites for the ReM.

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Granite Point Mortgage Trust

Nextcure

Payoneer Global

Purple Innovation

Petco Health and Wellness

Terawulf

The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.

Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

News for DiaMedica Therapeutics Inc Stock (DMAC)